“We also found that socioeconomic disparities, which disproportionately affected African American patients with kidney cancer, play an important role in impacting survival in RCC,” says Nirmish Singla, MD, MSc.
In this video, Nirmish Singla, MD, MSc, shares notable findings from the recent Urologic Oncology paper, “Socioeconomic determinants of racial disparities in survival outcomes among patients with renal cell carcinoma.” Singla is an associate professor of urology and oncology in the Brady Urological Institute at Johns Hopkins University in Baltimore, Maryland.
We started first off by analyzing all comers with RCC, and we stratified the population by essentially African American race vs Caucasian race. And then we went on and performed some additional sub analyses that were matched by stage. This included, on one end of the spectrum, patients who had non-metastatic small renal masses. And then on the complete other end of the spectrum, we also looked at patients who were diagnosed with metastatic disease at presentation. Then we also did some sub analyses by histologic subtypes in RCC. These included patients with clear cell RCC, which is the most common subtype of RCC, and also papillary RCC, which, interestingly, proportionately seems to affect African Americans at a higher rate compared with their Caucasian counterparts. And so overall, what we had found from our analysis was that African American patients with RCC seem to exhibit worse survival outcomes compared with Caucasian patients. And this was evident across all stages and histologies. And interestingly, also, this is despite the observation that African Americans were younger and also diagnosed at a relatively earlier stage. Furthermore, and what was striking about our study is that we also found that socioeconomic disparities, which disproportionately affected African American patients with kidney cancer, play an important role in impacting survival in RCC, and these are likely the factors that are driving inequalities in access to care and seem to be more magnified in patients who have advanced cases that would often benefit from this multidisciplinary expertise.
This transcript was edited for clarity.
Grant awarded to aid development of allogeneic CAR T treatment for RCC
April 29th 2024“This clinical study has the potential to demonstrate the value of Chimeric Antigen Receptor (CAR) T cell therapy in solid cancers such as kidney cancer with a high unmet medical need,” said Abla Creasey, PhD.
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
April 19th 2024“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.
Toripalimab plus axitinib approved in China for renal cell carcinoma
April 11th 2024The approval is based on findings from the phase 3 RENOTORCH trial, which showed that toripalimab plus axitinib prolonged progression-free survival and improved the objective response rate in patients with advanced RCC compared with sunitinib.